Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial

Key Points

• Biomarkers can predict response to neoadjuvant therapy in endocrine-resistant cases.
• Approximately 60% of participants showed improved outcomes using a palbociclib and anastrozole combination.
• Phase 2 trial assessed effectiveness in a targeted patient population over a specified timeframe.
• Further validation in larger, diverse cohorts may enhance treatment strategies across populations.